A Pilot Study to Assess the Efficacy of Tariquidar to Inhibit P-glycoprotein at the Human Blood–Brain Barrier with (R)-11C-Verapamil and PET
暂无分享,去创建一个
Stephan Kopp | Peter Chiba | Wolfgang Löscher | Oliver Langer | Rudolf Karch | Kurt Kletter | Martin Bauer | W. Löscher | P. Chiba | M. Zeitlinger | O. Langer | R. Karch | M. Bauer | Markus Müller | T. Feurstein | K. Kletter | Markus Müller | Markus Zeitlinger | Claudia C Wagner | Thomas Feurstein | S. Kopp | C. Wagner | Thomas Feurstein
[1] Stina Syvänen,et al. Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood–brain barrier can be studied with PET , 2006, NeuroImage.
[2] C. Wandel,et al. Increased drug delivery to the brain by P‐glycoprotein inhibition , 2000, Clinical pharmacology and therapeutics.
[3] Mark Lubberink,et al. Evaluation of Tracer Kinetic Models for Quantification of P-Glycoprotein Function using (R)-[11C]Verapamil and PET , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[4] Elizabeth Fox,et al. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor , 2007, Expert review of anticancer therapy.
[5] David J. Schlyer,et al. Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[6] R. Kim,et al. Differential in Vivo Sensitivity to Inhibition of P-glycoprotein Located in Lymphocytes, Testes, and the Blood-Brain Barrier , 2006, Journal of Pharmacology and Experimental Therapeutics.
[7] U. B. Nair,et al. Tariquidar, a Selective P-glycoprotein Inhibitor, Does Not Potentiate Loperamide’s Opioid Brain Effects in Humans despite Full Inhibition of Lymphocyte P-glycoprotein , 2008, Anesthesiology.
[8] Mark Muzi,et al. Imaging of Cyclosporine Inhibition of P-Glycoprotein Activity Using 11C-Verapamil in the Brain: Studies of Healthy Humans , 2009, Journal of Nuclear Medicine.
[9] Gert Luurtsema,et al. Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat. , 2005, Nuclear medicine and biology.
[10] P. Charlton,et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. , 2001, Cancer research.
[11] I. Pastan,et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. , 1999, Annual review of pharmacology and toxicology.
[12] P. Herscovitch,et al. P-Glycoprotein Function at the Blood–Brain Barrier Imaged Using 11C-N-Desmethyl-Loperamide in Monkeys , 2008, Journal of Nuclear Medicine.
[13] B. Långström,et al. Species differences in blood-brain barrier transport of three PET radioligands with emphasis on P-glycoprotein transport , 2008 .
[14] T. Fojo,et al. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[15] Alexander Hammers,et al. Pharmacoresistance in Epilepsy : A Pilot PET Study with the P-Glycoprotein Substrate R-[ 11 C ] verapamil ∗ † , 2007 .
[16] M. Lubberink,et al. Peripheral metabolism of (R)-[11C]verapamil in epilepsy patients , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[17] G. Woods,et al. Evidence that natural killer cells express mini P‐glycoproteins but not classic 170 kDa P‐glycoprotein , 2001, British journal of haematology.
[18] Treatment of drug resistance in epilepsy: one step at a time , 2006, The Lancet Neurology.
[19] B. Långström,et al. Species Differences in Blood-Brain Barrier Transport of Three Positron Emission Tomography Radioligands with Emphasis on P-Glycoprotein Transport , 2009, Drug Metabolism and Disposition.
[20] U. Germann,et al. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. , 1997, Anti-cancer drugs.
[21] G R Wilkinson,et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[22] D. Mankoff,et al. Imaging P‐glycoprotein Transport Activity at the Human Blood‐brain Barrier with Positron Emission Tomography , 2005, Clinical pharmacology and therapeutics.
[23] Wolfgang Löscher,et al. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases , 2005, Progress in Neurobiology.
[24] P. Jeffrey,et al. Development of a P-glycoprotein knockout model in rodents to define species differences in its functional effect at the blood-brain barrier. , 2006, Journal of pharmaceutical sciences.
[25] M. Gottesman,et al. Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.
[26] W. Löscher,et al. Tariquidar-Induced P-Glycoprotein Inhibition at the Rat Blood–Brain Barrier Studied with (R)-11C-Verapamil and PET , 2008, Journal of Nuclear Medicine.
[27] C. Higgins,et al. The molecular interaction of the high affinity reversal agent XR9576 with P‐glycoprotein , 1999, British journal of pharmacology.
[28] Yuichi Sugiyama,et al. In Vivo Evaluation of P-glycoprotein Function at the Blood-Brain Barrier in Nonhuman Primates Using [11C]Verapamil , 2006, Journal of Pharmacology and Experimental Therapeutics.
[29] P Bevan,et al. Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] Alexander Hammers,et al. Three‐dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe , 2003, Human brain mapping.